• Something wrong with this record ?

Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence

P. Kocián, M. Šedivcová, J. Drgáč, K. Cerná, J. Hoch, R. Kodet, J. Bartůňková, R. Špíšek, A. Fialová

. 2011 ; 72 (11) : 1022-1028. [pub] 20110816

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12022305

The prognosis of newly diagnosed colorectal cancer patients relies mostly on tumor-node metastasis classification. However, analyses of tumor-infiltrating lymphocytes and several molecular markers have also shown promising prognostic value. Mutations in the proto-oncogene KRAS, which occur early in colorectal carcinogenesis, have been demonstrated to be common in human colorectal cancer (CRC); however, their prognostic significance remains controversial. We examined the correlations between KRAS mutational status and tumor-infiltrating immune cells with respect to CRC recurrence. Mutations in KRAS were identified in 45.5% of the primary carcinomas in our cohort of patients: 65% in codon 12 and 35% in codon 13. Although codon 13 KRAS mutations were associated with disease relapse, they were present in both disease-free and relapsed patients. However, disease-free and relapsed patients differed markedly in their patterns of tumor-infiltrating immune cells. There was a trend toward decreased density of tumor-infiltrating lymphocytes (TILs) within the group of relapsed cases. In addition, relapsed patients with codon 13 mutations had markedly lower levels of tumor-infiltrating mature DC-LAMP(+) dendritic cells (DCs) and higher frequency of CD1a(+) cells compared with disease-free patients. Our data suggest that CRC patients with low levels of TILs, a high CD1a(+)/DC-LAMP(+) tumor-infiltrating DC ratio, and a KRAS mutation in codon 13 are at a high risk of disease recurrence.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022305
003      
CZ-PrNML
005      
20240827121138.0
007      
ta
008      
120806s2011 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.humimm.2011.07.312 $2 doi
035    __
$a (PubMed)21884745
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kocián, Petr, $d 1981- $7 xx0118297 $u Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Úvalu 84, 15006 Prague 5; Department of Surgery, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Úvalu 84, 15006 Prague 5, Czech Republic
245    10
$a Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence / $c P. Kocián, M. Šedivcová, J. Drgáč, K. Cerná, J. Hoch, R. Kodet, J. Bartůňková, R. Špíšek, A. Fialová
520    9_
$a The prognosis of newly diagnosed colorectal cancer patients relies mostly on tumor-node metastasis classification. However, analyses of tumor-infiltrating lymphocytes and several molecular markers have also shown promising prognostic value. Mutations in the proto-oncogene KRAS, which occur early in colorectal carcinogenesis, have been demonstrated to be common in human colorectal cancer (CRC); however, their prognostic significance remains controversial. We examined the correlations between KRAS mutational status and tumor-infiltrating immune cells with respect to CRC recurrence. Mutations in KRAS were identified in 45.5% of the primary carcinomas in our cohort of patients: 65% in codon 12 and 35% in codon 13. Although codon 13 KRAS mutations were associated with disease relapse, they were present in both disease-free and relapsed patients. However, disease-free and relapsed patients differed markedly in their patterns of tumor-infiltrating immune cells. There was a trend toward decreased density of tumor-infiltrating lymphocytes (TILs) within the group of relapsed cases. In addition, relapsed patients with codon 13 mutations had markedly lower levels of tumor-infiltrating mature DC-LAMP(+) dendritic cells (DCs) and higher frequency of CD1a(+) cells compared with disease-free patients. Our data suggest that CRC patients with low levels of TILs, a high CD1a(+)/DC-LAMP(+) tumor-infiltrating DC ratio, and a KRAS mutation in codon 13 are at a high risk of disease recurrence.
650    _2
$a antigeny CD1 $x biosyntéza $7 D018949
650    _2
$a karcinom $x diagnóza $x genetika $x patologie $x patofyziologie $7 D002277
650    _2
$a molekuly buněčné adheze neuronové $x biosyntéza $7 D015816
650    _2
$a buněčná diferenciace $x genetika $7 D002454
650    _2
$a pohyb buněk $x genetika $7 D002465
650    _2
$a kolorektální nádory $x diagnóza $x genetika $x patologie $x patofyziologie $7 D015179
650    _2
$a mutační analýza DNA $7 D004252
650    _2
$a dendritické buňky $x imunologie $x metabolismus $x patologie $7 D003713
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a GPI-vázané proteiny $x biosyntéza $7 D058851
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a lidé $7 D006801
650    _2
$a tumor infiltrující lymfocyty $x imunologie $x metabolismus $x patologie $7 D016246
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny $x genetika $7 D011518
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a ras proteiny $x genetika $7 D018631
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1#
$a Šedivcová, Monika. $7 xx0215746 $u Department of Pathology, Medical School and University Hospital, Charles University, 304 60 Pilsen, Czech Republic
700    1_
$a Drgáč, Jan $7 xx0321480 $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Úvalu 84, 15006 Prague 5, Czech Republic
700    1_
$a Černá, Kateřina $7 stk2007393952 $u Department of Pathology, Medical School and University Hospital, Charles University, 304 60 Pilsen, Czech Republic
700    1_
$a Hoch, Jiří, $d 1952- $7 jn19990209247 $u Department of Surgery, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Úvalu 84, 15006 Prague 5, Czech Republic
700    1_
$a Kodet, Roman, $d 1953- $7 nlk19990073380 $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Úvalu 84, 15006 Prague 5, Czech Republic
700    1_
$a Bartůňková, Jiřina, $d 1958- $7 jn20000400093 $u Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Úvalu 84, 15006 Prague 5, Czech Republic
700    1_
$a Špíšek, Radek, $d 1975- $7 nlk20030145288 $u Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Úvalu 84, 15006 Prague 5, Czech Republic
700    1_
$a Fialová, Anna, $d 1981- $7 stk2007393943 $u Department of Immunology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Úvalu 84, 15006 Prague 5, Czech Republic
773    0_
$w MED00002076 $t Human immunology $x 1879-1166 $g Roč. 72, č. 11 (2011), s. 1022-1028
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21884745 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20240827121135 $b ABA008
999    __
$a ok $b bmc $g 944218 $s 779602
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 72 $c 11 $d 1022-1028 $e 20110816 $i 1879-1166 $m Human immunology $n Hum Immunol $x MED00002076
LZP    __
$b NLK111 $a Pubmed-20120806/12/01

Find record

Citation metrics

Archiving options